News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Major Advocacy Issue: Optune

Al's Comment:

 

 We can not let Medicare deny access to FDA and NCCN approved brain tumor patients. It sets a dangerous precedent. 

 


Posted on: 02/21/2019

There is a big advocacy issue brewing.. I need everyone's help with this. Optune is a treatment for brain tumors, approved by the FDA 8 years ago, and is recommended as a standard of care by the NCCN guidelines. It offers a big improvement over the old standard of care. Medicare does not pay for it. Medicare will be having a meeting on March 6 to reconsider paying for it. We need to show Medicare that people are watching what they are up to. Follow the link below and sign up now to watch the meeting, then after the meeting there will be a public comment period for a few weeks - we will need to blitz them with letters as well as call our representatives in Congress about it. More details on that after the meeting - but sign up for the meeting (you can do it live in Baltimore or watch online - but you need to register either way). https://med.noridianmedicare.com/web/jadme/policies/dmd-articles/2019/cac-meeting-information-tumor-treatment-field-therapy-l34823


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740